4,056,379 Shares in Entrada Therapeutics, Inc. $TRDA Bought by 5AM Venture Management LLC

5AM Venture Management LLC bought a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,056,379 shares of the company's stock, valued at approximately $29,854,949. Entrada Therapeutics comprises 0.0% of 5AM Venture Management LLC's portfolio, making the stock its 3rd largest position. 5AM Venture Management LLC owned approximately 10.42% of Entrada Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC purchased a new position in Entrada Therapeutics in the 2nd quarter worth $114,000. Hsbc Holdings PLC purchased a new position in Entrada Therapeutics in the 2nd quarter worth $278,000. The Manufacturers Life Insurance Company purchased a new position in Entrada Therapeutics in the 2nd quarter worth $534,000. Nan Fung Group Holdings Ltd purchased a new position in Entrada Therapeutics in the 2nd quarter worth $361,244. Finally, Ieq Capital LLC purchased a new position in Entrada Therapeutics in the 2nd quarter worth $218,000. Hedge funds and other institutional investors own 86.39% of the company's stock.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88. Following the completion of the transaction, the insider owned 4,332,917 shares in the company, valued at approximately $32,670,194.18. This trade represents a 0.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kush Parmar sold 114,756 shares of Entrada Therapeutics stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $6.93, for a total value of $795,259.08. Following the transaction, the director owned 2,848,310 shares of the company's stock, valued at $19,738,788.30. The trade was a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 513,728 shares of company stock worth $3,586,368. Insiders own 9.49% of the company's stock.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $7.00 on Friday. The stock has a 50-day simple moving average of $7.08 and a two-hundred day simple moving average of $9.32. The firm has a market capitalization of $272.58 million, a P/E ratio of -1.77 and a beta of -0.26. Entrada Therapeutics, Inc. has a fifty-two week low of $5.02 and a fifty-two week high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). The company had revenue of $0.90 million for the quarter, compared to analysts' expectations of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. As a group, analysts forecast that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analysts Set New Price Targets

TRDA has been the subject of a number of research analyst reports. Weiss Ratings lowered Entrada Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 13th. HC Wainwright lowered Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Roth Capital restated a "buy" rating and issued a $11.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Finally, Guggenheim reduced their target price on Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a research note on Monday, June 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Entrada Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source